Ovid will discontinue development of OV101 (**oxadol), a delta (δ-selective **AA receptor agonist, in Angelman syndrome. Furthermore, Ovid does not plan to initiate further clinical studies of OV101 in Fragile X syndrome
https://investors.ovidrx.com/news-r...s-update-ov101-program-and-prioritization-its
- Forums
- ASX - By Stock
- OVID FAIL
Ovid will discontinue development of OV101 (**oxadol), a delta...
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.46 |
Change
-0.040(0.21%) |
Mkt cap ! $2.487B |
Open | High | Low | Value | Volume |
$19.50 | $19.59 | $19.35 | $1.200M | 61.70K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 20 | $19.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.47 | 1294 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 31 | 19.470 |
3 | 166 | 19.460 |
5 | 314 | 19.450 |
11 | 621 | 19.440 |
5 | 436 | 19.430 |
Price($) | Vol. | No. |
---|---|---|
19.480 | 595 | 2 |
19.490 | 302 | 4 |
19.500 | 766 | 5 |
19.510 | 1098 | 7 |
19.520 | 392 | 7 |
Last trade - 12.15pm 10/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online